Fmr LLC Has $233.58 Million Stake in China Biologic Products, Inc. (CBPO)
Fmr LLC grew its position in China Biologic Products, Inc. (NASDAQ:CBPO) by 9.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,065,269 shares of the biopharmaceutical company’s stock after buying an additional 184,720 shares during the quarter. Fmr LLC owned 7.58% of China Biologic Products worth $233,582,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Oppenheimer Asset Management Inc. acquired a new stake in shares of China Biologic Products during the 1st quarter worth approximately $156,000. Nomura Holdings Inc. acquired a new position in China Biologic Products during the first quarter valued at approximately $463,000. Jennison Associates LLC raised its position in China Biologic Products by 0.8% during the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after purchasing an additional 44 shares in the last quarter. First Trust Advisors LP raised its position in China Biologic Products by 35.9% during the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock valued at $1,158,000 after purchasing an additional 3,053 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in China Biologic Products by 15.5% during the first quarter. Nordea Investment Management AB now owns 13,200 shares of the biopharmaceutical company’s stock valued at $1,322,000 after purchasing an additional 1,768 shares in the last quarter. Institutional investors own 72.82% of the company’s stock.
A number of equities research analysts have weighed in on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of China Biologic Products in a report on Monday, June 12th. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, BidaskClub lowered China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. China Biologic Products has a consensus rating of “Hold” and an average price target of $132.00.
ILLEGAL ACTIVITY WARNING: “Fmr LLC Has $233.58 Million Stake in China Biologic Products, Inc. (CBPO)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/02/fmr-llc-has-233-58-million-stake-in-china-biologic-products-inc-cbpo.html.
Shares of China Biologic Products, Inc. (NASDAQ CBPO) opened at 92.27 on Monday. The firm has a 50-day moving average of $93.20 and a 200-day moving average of $104.03. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of 24.02 and a beta of 1.75. China Biologic Products, Inc. has a 12 month low of $88.25 and a 12 month high of $126.47.
China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. China Biologic Products’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 earnings per share. On average, analysts anticipate that China Biologic Products, Inc. will post $4.96 EPS for the current year.
About China Biologic Products
Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.